Orally active immunomodulatory agent that primarily targets macrophages. Inhibits TNF-α
secretion via interference of macrophage toll-like receptor (TLR) 4 and TLR 2/6 signaling pathway. Also reduces the secretion of pro-inflammatory cytokines IL1-β
, IL-10 and IFN-γ
. Antidiabetogenic; prevents IL-β
-induced pancreatic islet cell death in vitro
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
A potent immunomodulatory compound (S,R)-3-phenyl-4,5-dihydro-5-isoxasoleacetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of stre
Stosic-Grujicic et al.
In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models.
Stojanovic et al.
In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027.
Mangano et al.
The citations listed below are publications that use Tocris products. Selected citations for GIT 27 include:
Showing Results 1 - 1 of 1